Cargando…

Coping, social support and information in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: A 2-year retrospective cohort study

OBJECTIVES: Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension are severe diseases with complicated treatment that need care at specialist clinics. The aim was to investigate changes in the patients’ perceptions on coping, social support and received information when a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ivarsson, Bodil, Rådegran, Göran, Hesselstrand, Roger, Kjellström, Barbro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758958/ https://www.ncbi.nlm.nih.gov/pubmed/29326818 http://dx.doi.org/10.1177/2050312117749159

Ejemplares similares

Health-related quality of life, treatment adherence and psychosocial support in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
por: Ivarsson, Bodil, et al.
Publicado: (2018)

Perceptions of Received Information, Social Support, and Coping in Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension
por: Ivarsson, Bodil, et al.
Publicado: (2014)

Everyday life experiences of spouses of patients who suffer from pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
por: Ivarsson, Bodil, et al.
Publicado: (2019)

Outpatient specialist clinics for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the Nordic countries
por: Kjellström, Barbro, et al.
Publicado: (2020)

Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension
por: Kjellström, Barbro, et al.
Publicado: (2020)

Underfilling decreases left ventricular function in pulmonary arterial hypertension
por: Sjögren, Hannah, et al.
Publicado: (2021)

Sex-specific differences and survival in patients with idiopathic pulmonary arterial hypertension 2008–2016
por: Kjellström, Barbro, et al.
Publicado: (2019)

Prevalence of potential drug–drug interactions with disease‐specific treatments in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension: A registry study
por: Norell, Puck N., et al.
Publicado: (2022)

Atrioventricular plane displacement and regional function to predict outcome in pulmonary arterial hypertension
por: Lindholm, Anthony, et al.
Publicado: (2022)

Longitudinal changes in risk status in pulmonary arterial hypertension
por: Bouzina, Habib, et al.
Publicado: (2020)

Predicting mortality during long-term follow-up in pulmonary arterial hypertension
por: Kylhammar, David, et al.
Publicado: (2021)

Information Experiences and Needs in Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension
por: Ivarsson, Bodil, et al.
Publicado: (2014)

Five year risk assessment and treatment patterns in patients with chronic thromboembolic pulmonary hypertension
por: Kjellström, Barbro, et al.
Publicado: (2022)

Poor outcome of patients with pulmonary arterial hypertension with insufficient response to phosphodiesterase-5 inhibitors alone or in combination with other specific therapy: a registry-based study
por: Hjalmarsson, Clara, et al.
Publicado: (2020)

The Odyssey from Symptom to Diagnosis of Pulmonary Hypertension from the Patients and Spouses Perspective
por: Ivarsson, Bodil, et al.
Publicado: (2021)

Pulmonary arterial hypertension in systemic sclerosis—when criteria and pathobiology differ
por: Andréasson, Kristofer, et al.
Publicado: (2019)

Plasma matrix metalloproteinase 2 is associated with severity and mortality in pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2022)

Higher plasma fibroblast growth factor 23 levels are associated with a higher risk profile in pulmonary arterial hypertension
por: Bouzina, Habib, et al.
Publicado: (2019)

Early risk prediction in idiopathic versus connective tissue disease-associated pulmonary arterial hypertension: call for a refined assessment
por: Hjalmarsson, Clara, et al.
Publicado: (2021)

Plasma TRAIL and ANXA1 in diagnosis and prognostication of pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2023)

Societal costs associated to chronic thromboembolic pulmonary hypertension: A study utilizing linked national registries
por: Kjellström, Barbro, et al.
Publicado: (2023)

Respiratory rate modulation improves symptoms in patients with pulmonary hypertension
por: Kjellström, Barbro, et al.
Publicado: (2021)

Societal costs associated with pulmonary arterial hypertension: A study utilizing linked national registries
por: Runheim, Hannes, et al.
Publicado: (2023)

Circulating plasma microRNAs in systemic sclerosis-associated pulmonary arterial hypertension
por: Wuttge, Dirk M, et al.
Publicado: (2021)

Decreased biventricular longitudinal strain in patients with systemic sclerosis is mainly caused by pulmonary hypertension and not by systemic sclerosis per se
por: Lindholm, Anthony, et al.
Publicado: (2019)

Increased right atrial volume measured with cardiac magnetic resonance is associated with worse clinical outcome in patients with pre‐capillary pulmonary hypertension
por: Bredfelt, Anna, et al.
Publicado: (2018)

Risk assessment in pulmonary arterial hypertension: A step towards clinical implementation based on the 2022 ESC/ERS pulmonary hypertension guidelines
por: Ahmed, Abdulla, et al.
Publicado: (2023)

Matrix metalloproteinase 7 in diagnosis and differentiation of pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2019)

Plasma proteoglycan prolargin in diagnosis and differentiation of pulmonary arterial hypertension
por: Arvidsson, Mattias, et al.
Publicado: (2021)

Quality of life and functional status after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: A Swedish single‐center study
por: Kallonen, Janica, et al.
Publicado: (2023)

Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Humbert, Marc, et al.
Publicado: (2019)

Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: An Immunological Perspective
por: Koudstaal, Thomas, et al.
Publicado: (2020)

Cardiac Magnetic Resonance Imaging in Pulmonary Arterial Hypertension: Ready for Clinical Practice and Guidelines?
por: Kjellström, Barbro, et al.
Publicado: (2020)

Pulmonary artery dysfunction in chronic thromboembolic pulmonary hypertension
por: Chibana, Hidetoshi, et al.
Publicado: (2017)

Metabolic profile in endothelial cells of chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension
por: Smolders, V. F. E. D., et al.
Publicado: (2022)

CXCL13 in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Olsson, Karen M., et al.
Publicado: (2016)

Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
por: Benza, Raymond L., et al.
Publicado: (2022)

Plasma ADAMTS13 and von Willebrand factor in diagnosis and prediction of prognosis in pulmonary arterial hypertension
por: Ahmed, Abdulla, et al.
Publicado: (2021)

Pulmonary blood density in systemic sclerosis – a novel non-invasive measure of pulmonary arterial hypertension?
por: Kanski, Mikael, et al.
Publicado: (2009)

Right atrial volume measured by cardiac magnetic resonance correlates with NT-ProBNP and invasive right atrial pressure in pulmonary hypertension, with and without systemic sclerosis
por: Gyllenhammar, Tom, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_sqc49oo38hra2cmk70jtpcku5p